高级检索
当前位置: 首页 > 详情页

miR-28-3p suppresses gastric cancer growth and EMT-driven metastasis by targeting the ARF6/Hedgehog axis

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Medical Oncology, The First People's Hospital of Yunnan Province/The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, 650000, China [2]Faculty of Medicine, Kunming University of Science and Technology, Kunming, 650000, China. [3]Department of General Surgery, The First People's Hospital of Yunnan Province/The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, 650000, China.
出处:
ISSN:

关键词: Gastric cancer miR-28–3p ADP ribosylation factor 6 Epithelial-mesenchymal transition Hedgehog signaling pathway

摘要:
Gastric cancer (GC), among the most prevalent malignant tumors globally, demonstrates a rapid metastasis rate leading to high mortality. While microRNAs (miRNAs) have been recognized as critical regulators of tumor progression, the specific role of miR-28-3p in GC remains unclear. In this study, we demonstrate that miR-28-3p acts as a tumor suppressor by inhibiting GC cell proliferation and EMT-driven migration in vitro, as well as tumor growth and metastasis in vivo. Mechanistically, miR-28-3p directly targets ADP ribosylation factor 6 (ARF6), a small GTPase identified as an oncogene in GC. We reveal that ARF6 is significantly upregulated in GC and activates the GLI1/2-dependent Hedgehog signaling pathway, promoting tumor growth and EMT. Notably, ARF6 knockdown mitigates the pro-tumor effects caused by miR-28-3p deficiency, while combined ARF6 inhibition and Hedgehog pathway suppression exhibit synergistic anti-tumor effects. This study establishes the miR-28-3p-ARF6-Hedgehog signaling axis as a critical regulatory pathway in GC progression. Our findings provide novel insights into GC pathogenesis and highlight the therapeutic potential of targeting this axis for innovative treatment strategies.Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
最新[2025]版:
大类 | 4 区 生物学
小类 | 3 区 生化研究方法 3 区 生物工程与应用微生物 4 区 生化与分子生物学 4 区 细胞生物学
JCR分区:
出版当年[2024]版:
最新[2023]版:
Q3 BIOCHEMICAL RESEARCH METHODS Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q4 CELL BIOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2023版]

第一作者:
第一作者机构: [1]Department of Medical Oncology, The First People's Hospital of Yunnan Province/The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, 650000, China [2]Faculty of Medicine, Kunming University of Science and Technology, Kunming, 650000, China.
共同第一作者:
通讯作者:
通讯机构: [1]Department of Medical Oncology, The First People's Hospital of Yunnan Province/The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, 650000, China [2]Faculty of Medicine, Kunming University of Science and Technology, Kunming, 650000, China. [3]Department of General Surgery, The First People's Hospital of Yunnan Province/The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, 650000, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:87470 今日访问量:0 总访问量:721 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西山区金碧路157号